Clinical trials: Salmonella Typhi Infection
Cholera, Typhoid
Studies of Immune Responses to Orally Administered Vaccines in Developing Country
The efficacy and immunogenicity of enteric vaccines have generally been found to be lower in children in the developed than in the developing countries.
- Trial name
- NCT01019083
- Testing
- Control, Zinc Sulphate, Albendazole and Secnidazole
- Where
- Bangladesh
- Volunteers
- 1,016 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Vaccine
Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian
Vi-DT Typhoid vaccine is a novel vaccine. This study will be done to know the long-term protection and persistent antibody by measured the antibody titer after 2,3,4 and 5 years after immunization.
- Trial name
- NCT04741828
- Testing
- Vi-DT Typhoid Conjugate Vaccine
- Where
- 2 sites in Indonesia
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Typhoid Fever
Commercial Typhoid Tests Validation
The study aims to perform a head to head comparison of 11 typhoid tests currently in the market and simultaneously develop a sample set that can be used in future evaluations of emerging technologies.
- Trial name
- NCT04673487
- Testing
- 1. SD Bioline Salmonella Typhi IgG/IgM Fast test, 2. Typhidot Rapid IgG/IgM combo test, 3. TUBEX TF test, 4.Typhoid IgG/IgM Combo Rapid Test CE, 5. Enterocheck WB test, 6. Test-itTM Typhoid IgM test
- Where
- Kenya
- Volunteers
- 2,000 people
- Sponsor
- Kenya Medical Research Institute
Enteric Fever, Typhoid Fever
Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever
The investigators aim to compare two antibiotic treatments for enteric (typhoid) fever. Three hundred patients at Patan Hospital will be enrolled in the study.
- Trial name
- NCT01421693
- Testing
- Ceftriaxone, Gatifloxacin
- Where
- 2 sites in Nepal
- Volunteers
- 300 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Typhoid Fever
The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial)
Typhoid and paratyphoid (enteric) fever affects more than 11 million children and adults globally each year including 7 million in South Asia.
- Trial name
- ACT-South Asia (NCT04349826)
- Testing
- Azithromycin, Cefixime
- Where
- Nepal
- Volunteers
- 2,150 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Typhoid Fever
Effectiveness of a Typhoid Conjugate Vaccine in DRC
This is a prospective cohort evaluation of vaccine effectiveness of a single dose of Typbar-TCV® against symptomatic blood culture-confirmed typhoid fever when administered through a mass vaccination campaign to children 9 months…
- Trial name
- TyVECO (NCT05119426)
- Testing
- Vi-TT
- Where
- 25 sites in Democratic Republic of the Congo
- Volunteers
- 48,000 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Typhoid, Paratyphoid Fever
Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam
This study is part of International Vaccine Institutes (IVI)'s typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries.
- Trial name
- NCT00131820
- Testing
- Typhoid Vi vaccine, Hepatitis A (control)
- Where
- Vietnam
- Volunteers
- 100,742 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Typhoid Fever
Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants
The purpose of this study is to evaluate the safety, immunogenicity, and compatibility of our Vi-rEPA conjugate administered to infants with their routine vaccinations.
- Trial name
- NCT00342628
- Testing
- Vi-rEPA conjugate vaccine for typhoid fever, Hib-TT, DTP
- Where
- Vietnam
- Volunteers
- 301 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Typhoid, Paratyphoid Fever
Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever
This study is part of the International Vaccine Institute's (IVI's) typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries.
- Trial name
- NCT00125008
- Testing
- Typhoid Vi vaccine, Hepatitis A vaccine
- Where
- India
- Volunteers
- 37,673 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Typhoid
Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine
This is a Phase I, Randomized, observer-blinded, age de-escalating study. The study objectives are: 1. To evaluate the safety of 25 μg of Vi-DT typhoid conjugate vaccine administered at 0 and 4 weeks. 2.
- Trial name
- NCT02645032
- Testing
- Vi-DT, Typhim Vi®, VAXIGRIP®
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Extensively Drug-Resistant Typhoid Fever, Typhoid Fever
This Randomized Controlled Trial Evaluates the Comparative Efficacy of Intravenous Meropenem Alone Versus Intravenous Meropenem Combined With Oral Azithromycin in Children Aged 6 Months to Under 5 Years Diagnosed With Blood Culture-confirmed Extensively Drug-resistant Uncomplicated Typhoid Fever
This randomized controlled trial evaluates the comparative efficacy of intravenous meropenem alone versus intravenous meropenem combined with oral azithromycin in children aged 6 months to under 5 years diagnosed with blood…
- Conditions
- Extensively Drug-Resistant Typhoid Fever, Typhoid Fever, Salmonella Typhi Infection
- Trial name
- XDR-TY (NCT07445282)
- Testing
- Meropenem, Azithromycin + Metronidazole
- Where
- Pakistan
- Volunteers
- 90 people
- Sponsor
- Sheikh Zayed Medical College
Visceral Leishmaniasis, Human African Trypanosomiasis
Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever)
Tropical fevers have been a diagnostic challenge from the antiquity. Nowadays, despite the availability of good diagnostic capacities, undifferentiated febrile illnesses continue to be a thorny problem for travel physicians.
- Conditions
- Visceral Leishmaniasis, Human African Trypanosomiasis, Enteric Fever, Melioidosis
- Trial name
- NCT01766830
- Testing
- rk28 ICT, IT LEISH (rK39), Immunochromatographic HAT test
- Where
- 7 sites in Cambodia, Democratic Republic of the Congo and 2 more
- Volunteers
- 1,927 people
- Sponsor
- University Hospital, Geneva
Typhoid
Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh
This is a double blinded, randomized-controlled, non-inferiority trial of a typhoid conjugate vaccine, Typhocon (Vi- polysaccharide conjugated to diphtheria toxoid, Vi-DT), manufactured by a local company, Incepta Vaccine…
- Trial name
- NCT05475379
- Testing
- Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT)
- Where
- Bangladesh
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Undifferentiated Febrile Illness
Nepal Undifferentiated Febrile Illness Trial
The purpose of the study is to determine whether azithromycin or cotrimoxazole is the best empirical treatment for undifferentiated febrile illness in Nepal
- Trial name
- NUFIT (NCT02773407)
- Testing
- Azithromycin, Co-trimoxazole
- Where
- 2 sites in Nepal
- Volunteers
- 330 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Safety Issues
Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I)
This study is to assess the safety of Vi-DT vaccine in adults and children.
- Trial name
- NCT03109600
- Testing
- Vi-DT (Bio Farma), Vi polysaccharide vaccine, Influenzae vaccine
- Where
- 2 sites in Indonesia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Typhoid, Fever
Efficacy of Levofloxacin Versus Ciprofloxacin in the Treatment of Childhood Typhoid Fever
Sample size of 360 children with typhoid fever were enrolled and randomly divided in two groups. All the children were enrolled in the trial from Pediatrics emergency. Informed consent was obtained from parents.
- Trial name
- NCT07150065
- Testing
- Levofloxacin, ciprofloxacin
- Where
- Pakistan
- Volunteers
- 360 people
- Sponsor
- Avicenna Medical College Lahore
Typhoid Fever
Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana
A cluster-randomised controlled Phase IV trial (cRCT) assessing the impact of a Vi-Polysaccharide conjugate vaccine in preventing typhoid infection in Asante Akim, Ghana (TyVEGHA) with a primary endpoint of determining the total…
- Trial name
- TyVEGHA (NCT04852185)
- Testing
- Vi-TT, MCV-A vaccine
- Where
- Ghana
- Volunteers
- 23,000 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Safety Issues, Immunogenicity
Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants
This study is to assess the safety and immunogenicity of Vi-DT vaccine in adults, adolescent, children and infants.
- Trial name
- NCT03460405
- Testing
- Vi-DT Vaccine, Vi Polysaccharide Vaccine, IPV Vaccine
- Where
- 2 sites in Indonesia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Typhoid Vaccination, Typhoid
ZyVac-TCV Bangladesh Study
This is a prospective closed cohort, open-label, phase III effectiveness study using a test-negative design of a typhoid conjugate vaccine, ZyVac® TCV (purified Vi capsular polysaccharide of Salmonella Typhi conjugated to tetanus…
- Conditions
- Typhoid Vaccination, Typhoid, Typhoid Fever
- Trial name
- NCT06757283
- Testing
- Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV
- Where
- Bangladesh
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Ebola Virus Disease, Malaria
Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC
A mobile suitcase laboratory for EBOV point-of-care (POC) detection at Ebola treatment centers was successfully implemented in Guinea during the large Ebola virus disease (EVD) outbreak in West-Africa 2014-2015.
- Conditions
- Ebola Virus Disease, Malaria, Typhoid Fever, Dengue Fever
- Trial name
- MobEboDRC (NCT04235361)
- Testing
- Differential RPA tests
- Where
- 4 sites in Canada, Democratic Republic of the Congo and 2 more
- Volunteers
- 500 people
- Sponsor
- University of Stirling